AU2013296493B2 - Methods for treatment of atherosclerosis - Google Patents

Methods for treatment of atherosclerosis Download PDF

Info

Publication number
AU2013296493B2
AU2013296493B2 AU2013296493A AU2013296493A AU2013296493B2 AU 2013296493 B2 AU2013296493 B2 AU 2013296493B2 AU 2013296493 A AU2013296493 A AU 2013296493A AU 2013296493 A AU2013296493 A AU 2013296493A AU 2013296493 B2 AU2013296493 B2 AU 2013296493B2
Authority
AU
Australia
Prior art keywords
statin
pct
peptide
simvastatin
atorvastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013296493A
Other languages
English (en)
Other versions
AU2013296493A1 (en
Inventor
Mark BAMBERGER
Brian BLAKEY
D. Travis Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Biotherapeutics Inc
Original Assignee
Stealth Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Biotherapeutics Inc filed Critical Stealth Biotherapeutics Inc
Publication of AU2013296493A1 publication Critical patent/AU2013296493A1/en
Priority to AU2018202068A priority Critical patent/AU2018202068A1/en
Application granted granted Critical
Publication of AU2013296493B2 publication Critical patent/AU2013296493B2/en
Assigned to STEALTH BIOTHERAPEUTICS INC. reassignment STEALTH BIOTHERAPEUTICS INC. Request for Assignment Assignors: STEALTH PEPTIDES INTERNATIONAL, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2013296493A 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis Active AU2013296493B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018202068A AU2018202068A1 (en) 2012-08-02 2018-03-23 Methods for treatment of atherosclerosis

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261678992P 2012-08-02 2012-08-02
US61/678,992 2012-08-02
US201261695807P 2012-08-31 2012-08-31
US201261695850P 2012-08-31 2012-08-31
US61/695,807 2012-08-31
US61/695,850 2012-08-31
PCT/US2013/053007 WO2014022551A1 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202068A Division AU2018202068A1 (en) 2012-08-02 2018-03-23 Methods for treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
AU2013296493A1 AU2013296493A1 (en) 2015-02-26
AU2013296493B2 true AU2013296493B2 (en) 2018-04-26

Family

ID=50028503

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013296493A Active AU2013296493B2 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis
AU2013296494A Active AU2013296494B2 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis
AU2018202068A Abandoned AU2018202068A1 (en) 2012-08-02 2018-03-23 Methods for treatment of atherosclerosis
AU2018202197A Abandoned AU2018202197A1 (en) 2012-08-02 2018-03-27 Methods for treatment of atherosclerosis

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2013296494A Active AU2013296494B2 (en) 2012-08-02 2013-07-31 Methods for treatment of atherosclerosis
AU2018202068A Abandoned AU2018202068A1 (en) 2012-08-02 2018-03-23 Methods for treatment of atherosclerosis
AU2018202197A Abandoned AU2018202197A1 (en) 2012-08-02 2018-03-27 Methods for treatment of atherosclerosis

Country Status (8)

Country Link
US (5) US10188693B2 (https=)
EP (6) EP3485897A1 (https=)
JP (5) JP2015529655A (https=)
CN (3) CN104661670A (https=)
AU (4) AU2013296493B2 (https=)
CA (2) CA2880643A1 (https=)
HK (2) HK1210953A1 (https=)
WO (2) WO2014022552A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009141A1 (en) * 2011-12-09 2016-04-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
HK1210953A1 (en) * 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
WO2015183985A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including naphthoquinones and uses thereof
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
RU2623876C2 (ru) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Фармацевтическая композиция для лечения гиперлипидемии
WO2016190852A1 (en) * 2015-05-26 2016-12-01 Stealth Peptides International, Inc. Therapeutic compositions including chromanyl compounds, variants and analogues thereof, and uses thereof
WO2017070445A1 (en) * 2015-10-23 2017-04-27 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of treatment of rhabdomyolysis
US11355245B2 (en) * 2016-05-03 2022-06-07 International Business Machines Corporation Identifying and ranking risk factors using trained predictive models
CA3035875A1 (en) * 2016-09-20 2018-03-29 Aarhus Universitet Compounds for treatment of lipoprotein metabolism disorders
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
CN110914287A (zh) 2017-04-05 2020-03-24 隐形生物治疗公司 Boc-d-arg-dmt-lys-(boc)-phe-nh2的结晶盐形式
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
GB202005439D0 (en) 2020-04-14 2020-05-27 Aurigen Medical Ltd A device for occlusion of a left a trial appendage of a heart

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
WO2011116007A1 (en) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
WO2003014145A2 (en) * 2001-08-10 2003-02-20 Novartis Ag Peptides that bind to atherosclerotic lesions
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP4879020B2 (ja) * 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド 細胞に分子を送達する方法及び担体複合体
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
MX2008009591A (es) 2006-01-30 2008-09-24 Israel Ben David Bryson Composiciones y metodos para tratar a pacientes con enfermedades cardiovasculares, cerebrovasculares y otras enfermedades vasculares.
US10568860B2 (en) * 2006-08-30 2020-02-25 Kowa Co., Ltd. Pharmaceutical composition containing statin-encapsulated nanoparticle
US20090186832A1 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
EP3103467A1 (en) * 2008-02-07 2016-12-14 Cornell University Methods for preventing or treating insulin resistance
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
KR20130118925A (ko) * 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
HK1210953A1 (en) * 2012-08-02 2016-05-13 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035640A2 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
WO2011025734A1 (en) * 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
WO2011116007A1 (en) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Also Published As

Publication number Publication date
CN110090304A (zh) 2019-08-06
US10201585B2 (en) 2019-02-12
JP2015524439A (ja) 2015-08-24
CA2880643A1 (en) 2014-02-06
US20180339012A1 (en) 2018-11-29
JP2019108389A (ja) 2019-07-04
US20180344797A1 (en) 2018-12-06
AU2013296493A1 (en) 2015-02-26
EP2879689A1 (en) 2015-06-10
AU2013296494B2 (en) 2018-04-26
WO2014022551A1 (en) 2014-02-06
EP2879688A1 (en) 2015-06-10
EP3485897A1 (en) 2019-05-22
WO2014022552A1 (en) 2014-02-06
CN104661670A (zh) 2015-05-27
EP2879689A4 (en) 2015-12-16
US10188693B2 (en) 2019-01-29
HK1210953A1 (en) 2016-05-13
US20150157685A1 (en) 2015-06-11
JP2018012726A (ja) 2018-01-25
EP3300740A1 (en) 2018-04-04
JP2015529655A (ja) 2015-10-08
CN104768564A (zh) 2015-07-08
EP2879688A4 (en) 2015-12-16
CA2880648A1 (en) 2014-02-06
US20200000870A1 (en) 2020-01-02
AU2018202068A1 (en) 2018-04-19
HK1210962A1 (en) 2016-05-13
JP2018016637A (ja) 2018-02-01
AU2018202197A1 (en) 2018-04-26
EP3132800A1 (en) 2017-02-22
AU2013296494A1 (en) 2015-02-26
US20150283200A1 (en) 2015-10-08
EP3662921A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
AU2013296493B2 (en) Methods for treatment of atherosclerosis
KR101356335B1 (ko) 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
JP2013023499A5 (https=)
JP6196225B2 (ja) 糖尿病新規発症低減用組成物
US20110251275A1 (en) Omega-3 fatty acids for reduction of lp-pla2 levels
RU2013156848A (ru) Лечение антителами против pcsk9
SI2443246T1 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
JP2008533029A (ja) スタチン及びω−３脂肪酸による治療方法、並びにそれらの複合生成物
FI3448426T3 (fi) Menetelmiä familiaalista hyperkolesterolemiaa sairastavien potilaiden hoitoon
JP2015529655A5 (https=)
JP2006503001A5 (https=)
IL292829A (en) Fixed dose combinations containing etc1002 and one or more statins to treat or reduce cardiovascular risk
Atar et al. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances
Meagher Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story
CN119302932A (zh) 用于治疗高脂血症的药物组合
AU2016402338A1 (en) Combinational compositions and methods of use thereof
Maritz Efficacy and dangers of statin therapy
KR20080015789A (ko) 신규의 트리글리세리드 저하제
Gotto Jr et al. Twenty-five years of statins: where do we go from here?
KR101830977B1 (ko) 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
US20170296499A1 (en) Combinational compositions and methods of use thereof
Edwards et al. Atorvastatin and cobicistat-elvitegravir interaction causing myopathy in the setting of biliary obstruction
KR101954568B1 (ko) 오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
NZ807894B2 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
Badshah et al. SAFETY AND EFFICACY OF BEMPEDOIC ACID AS A MONO AND COMBINED THERAPY IN STATIN HYPERLIPIDEMIC PATIENT: A SYSTEMATIC REVIEW

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: STEALTH BIOTHERAPEUTICS INC.

Free format text: FORMER OWNER(S): STEALTH PEPTIDES INTERNATIONAL, INC.